Please try another search
For the nine months ended 31 May 2015, Oncologix Tech Inc revenues increased 34% to $3.6M. Net loss before extraordinary items increased 30% to $1.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest and finance charges increase of 72% to $1.1M (expense), General and administrative increase of 36% to $1.4M (expense).
Period Ending: | May 31, 2015 | Feb 28, 2015 | Nov 30, 2014 | Aug 31, 2014 |
---|---|---|---|---|
Total Revenue | 1.24 | 1.23 | 1.16 | 0.98 |
Gross Profit | 0.35 | 0.32 | 0.3 | -0.02 |
Operating Income | -0.1 | -0.14 | -0.17 | -0.18 |
Net Income | -0.53 | -0.53 | -0.44 | -0.26 |
Period Ending: | May 31, 2015 | Feb 28, 2015 | Nov 30, 2014 | Aug 31, 2014 |
---|---|---|---|---|
Total Assets | 3.85 | 3.61 | 3.59 | 2.14 |
Total Liabilities | 5.04 | 4.75 | 4.62 | 2.8 |
Total Equity | -1.19 | -1.13 | -1.03 | -0.66 |
Period Ending: | May 31, 2015 | Feb 28, 2015 | Nov 30, 2014 | Aug 31, 2014 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.39 | -0.36 | -0.2 | -0.63 |
Cash From Investing Activities | -0.56 | -0.56 | -0.56 | -0.07 |
Cash From Financing Activities | 1.06 | 0.94 | 0.82 | 0.68 |
Net Change in Cash | 0.1 | 0.01 | 0.06 | -0.02 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review